Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.joen.2022.01.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of Covid-19 on harm reduction policies in Iran: an interrupted time series analysis.
Harm Reduct J
January 2025
Department of Anesthesiology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Background: The global emergence of the Covid-19 pandemic in 2019 posed unprecedented challenges to healthcare systems, disrupting routine services and necessitating swift adaptations. Harm reduction programs, vital for addressing substance use-related health risks, faced unique challenges during the pandemic, impacting vulnerable populations. This study focuses on the repercussions of Covid-19 on harm reduction policies in Iran, specifically examining the distribution of condoms, syringes, and methadone to high-risk individuals attending Triangle Centers.
View Article and Find Full Text PDFThe impact of the Covid-19 pandemic on outpatient visits for patients with cancer in Iran: an interrupted time series analysis.
Arch Public Health
January 2025
Department of Anesthesiology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Lorestan, Iran.
Background: The Covid-19 pandemic has posed unprecedented challenges to healthcare systems worldwide, affecting routine medical services, including for cancer patients. This study investigates the impact of the Covid-19 pandemic on outpatient visits for patients with cancer in Iran.
Methods: We conducted an interrupted time series analysis (ITSA) on data collected from electronic medical records.
Integration of metabolomics methodologies for the development of predictive models for mortality risk in elderly patients with severe COVID-19.
BMC Infect Dis
January 2025
Department of Critical Care Medicine, Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, Heilongjiang Province, China.
Background: The rapid evolution of the COVID-19 pandemic and subsequent global immunization efforts have rendered early metabolomics studies potentially outdated, as they primarily involved non-exposed, non-vaccinated populations. This paper presents a predictive model developed from up-to-date metabolomics data integrated with clinical data to estimate early mortality risk in critically ill COVID-19 patients. Our study addresses the critical gap in current research by utilizing current patient samples, providing fresh insights into the pathophysiology of the disease in a partially immunized global population.
View Article and Find Full Text PDFHealth care resource utilization and costs of Medicare-enrolled patients with HR+/HER2- metastatic breast cancer treated with a CDK4/6i in the first-line setting.
J Manag Care Spec Pharm
January 2025
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle.
Background: The introduction of cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6is) has transformed the treatment landscape for patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC). To our knowledge, no studies have quantified health care resource utilization (HRU) or economic burden following CDK4/6i initiation in the Medicare population.
Objective: To describe HRU and quantify health care costs among Medicare-enrolled patients with HR+ HER2- MBC treated with CDK4/6is in the first-line setting.
Objective: To describe the lived experience of patients with NORSE and explore quality of life (QOL) for patients and their caregivers.
Background: NORSE is a rare condition characterized by refractory status epilepticus, often of unknown cause, in a previously neurologically healthy individual. Febrile infection-related epilepsy syndrome (FIRES) is a subset of NORSE.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!